Language Impairment in Alzheimer's Disease: An Updated Narrative Review of Digital Assessment, Social Interventions, and Medical Treatment, 2016-2026.
- 1Department of Applied Linguistics, Faculty of Informatics and Management, University of Hradec Kralove, Hradec Kralove, Czech Republic.
Abstract
Language impairment is a core clinical manifestation of Alzheimer's disease (AD) that profoundly affects autonomy, decision-making, and social participation. Building upon the 2015 review by Kuca et al., this narrative review synthesizes empirical evidence from 2016 through 2026. A structured Web of Science Core Collection search retrieved 154 records. Following screening, 66 records were excluded and 88 full-text reports were appraised, of which 13 were consolidated, yielding 75 cited core empirical studies alongside foundational diagnostic, neuropathological, and trial benchmarks. Four main areas are synthesized. First, progressive linguistic decline across clinical stages is characterized, delineating typical amnestic AD dementia, mild cognitive impairment due to AD, and the logopenic variant of primary progressive aphasia (lvPPA), highlighting the necessity of biological amyloid and tau biomarker confirmation. Second, automated speech and natural language processing biomarkers have emerged as scalable tools predicting progression to dementia and detecting biological amyloid-beta positivity; however, real-world translation remains constrained by demographic bias, cross-linguistic variations, acoustic sensitivity, and privacy issues. Third, non-pharmacological interventions, including structured language stimulation and naming therapy, demonstrate measurable task-specific improvements; nevertheless, gains are largely restricted to trained items with minimal transfer to everyday discourse. Caregiver communication training programs reliably improve dyadic interactions and mitigate caregiver distress. Fourth, approved symptomatic drugs do not directly reverse language decline, and add-on memantine in the randomized ROMEO-AD trial produced no statistically significant language benefit over donepezil alone. Disease-modifying anti-amyloid antibodies offer biological intervention for biomarker-positive lvPPA, but pivotal trials lacked primary speech endpoints, establishing eligibility rather than demonstrated language recovery. Non-invasive neuromodulation remains preliminary and requires sham-controlled trials. Communication should be recognized as a distinct clinical outcome in trial designs, prioritizing standardized speech endpoints to assess disease-modifying therapies.
Related
- Dietary Patterns and Nutritional Interventions for Cognitive Impairment in Parkinson’s Disease: A Critical Narrative Review
- Olea europaea-derived interventions and cognitive outcomes across cognitive aging, mild cognitive impairment, and Alzheimer's disease: a systematic review of controlled clinical studies
- Hypertension, Atrial Fibrillation, and Orthostatic Hypotension in Older Adults: Blood Pressure Assessment and Treatment Decisions—A Narrative Review
- Integrating Biological Maturity into Fitness Assessment and Physical Activity Interventions in Children and Adolescents: A Narrative Review
- From movement to mood regulation: exercise-based digital interventions using mobile health and ecological momentary assessment for mental health and cognitive function in older adults: a narrative review
BibTeX
@article{klimova2026language,
title = {{Language Impairment in Alzheimer's Disease: An Updated Narrative Review of Digital Assessment, Social Interventions, and Medical Treatment, 2016-2026.}},
author = {Blanka Klimova},
journal = {Clinical interventions in aging},
year = {2026},
month = oct,
doi = {10.2147/cia.s633855},
url = {https://europepmc.org/article/MED/42968820},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Language Impairment in Alzheimer's Disease: An Updated Narrative Review of Digital Assessment, Social Interventions, and Medical Treatment, 2016-2026.
AU - Blanka Klimova
PY - 2026
DA - 2026/10/28
JO - Clinical interventions in aging
DO - 10.2147/cia.s633855
UR - https://europepmc.org/article/MED/42968820
AB - Language impairment is a core clinical manifestation of Alzheimer's disease (AD) that profoundly affects autonomy, decision-making, and social participation. Building upon the 2015 review by Kuca et al., this narrative review synthesizes empirical evidence from 2016 through 2026. A structured Web of Science Core Collection search retrieved 154 records. Following screening, 66 records were excluded and 88 full-text reports were appraised, of which 13 were consolidated, yielding 75 cited core empirical studies alongside foundational diagnostic, neuropathological, and trial benchmarks. Four main areas are synthesized. First, progressive linguistic decline across clinical stages is characterized, delineating typical amnestic AD dementia, mild cognitive impairment due to AD, and the logopenic variant of primary progressive aphasia (lvPPA), highlighting the necessity of biological amyloid and tau biomarker confirmation. Second, automated speech and natural language processing biomarkers have emerged as scalable tools predicting progression to dementia and detecting biological amyloid-beta positivity; however, real-world translation remains constrained by demographic bias, cross-linguistic variations, acoustic sensitivity, and privacy issues. Third, non-pharmacological interventions, including structured language stimulation and naming therapy, demonstrate measurable task-specific improvements; nevertheless, gains are largely restricted to trained items with minimal transfer to everyday discourse. Caregiver communication training programs reliably improve dyadic interactions and mitigate caregiver distress. Fourth, approved symptomatic drugs do not directly reverse language decline, and add-on memantine in the randomized ROMEO-AD trial produced no statistically significant language benefit over donepezil alone. Disease-modifying anti-amyloid antibodies offer biological intervention for biomarker-positive lvPPA, but pivotal trials lacked primary speech endpoints, establishing eligibility rather than demonstrated language recovery. Non-invasive neuromodulation remains preliminary and requires sham-controlled trials. Communication should be recognized as a distinct clinical outcome in trial designs, prioritizing standardized speech endpoints to assess disease-modifying therapies.
SN - 1176-9092
SN - 1178-1998
ER -